Edition:
United Kingdom

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

13.91USD
16 Oct 2018
Change (% chg)

$0.81 (+6.18%)
Prev Close
$13.10
Open
$13.19
Day's High
$13.97
Day's Low
$12.87
Volume
102,290
Avg. Vol
115,527
52-wk High
$48.74
52-wk Low
$12.52

Chart for

About

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in... (more)

Overall

Beta: 4.21
Market Cap(Mil.): $1,122.56
Shares Outstanding(Mil.): 28.90
Dividend: --
Yield (%): --

Financials

  FPRX.OQ Industry Sector
P/E (TTM): -- 86.20 32.69
EPS (TTM): -4.24 -- --
ROI: -29.38 0.73 14.32
ROE: -31.27 1.82 16.04

BRIEF-Five Prime Therapeutics Announces Collaboration With Roche

* FIVE PRIME THERAPEUTICS ANNOUNCES COLLABORATION WITH ROCHE TO DEVELOP COMPANION DIAGNOSTICS FOR TARGETED IMMUNO-ONCOLOGY INVESTIGATIONAL DRUG CANDIDATES

30 May 2018

BRIEF-Five Prime Therapeutics Reports Q1 Loss Per Share $0.63

* FIVE PRIME THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

BRIEF-Five Prime Therapeutics Appointed Linda Rubinstein As Interim CFO

* FIVE PRIME THERAPEUTICS INC - ON APRIL 13 APPOINTED LINDA RUBINSTEIN AS INTERIM CHIEF FINANCIAL OFFICER - SEC FILING

17 Apr 2018

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥4,469 --
Novartis AG (NOVN.S) CHF84.08 +1.62
AstraZeneca plc (AZN.L) 5,763.00 +144.00
Eli Lilly And Co (LLY.N) $111.03 +0.41
ArQule, Inc. (ARQL.OQ) $4.66 +0.39

Earnings vs. Estimates